Results 91 to 100 of about 336,084 (346)

A comparative study of gene-expression data of basal cell carcinoma and melanoma reveals new insights about the two cancers. [PDF]

PLoS ONE, 2012
A comparative analysis of genome-scale transcriptomic data of two types of skin cancers, melanoma and basal cell carcinoma in comparison with other cancer types, was conducted with the aim of identifying key regulatory factors that either cause or ...
Kun Xu, Xizeng Mao, Minesh Mehta, Juan Cui, Chi Zhang, Ying Xu   +5 more
doaj   +1 more source

Targeting the AKT/mTOR pathway attenuates the metastatic potential of colorectal carcinoma circulating tumor cells in a murine xenotransplantation model

Molecular Oncology, EarlyView.
Dual targeting of AKT and mTOR using MK2206 and RAD001 reduces tumor burden in an intracardiac colon cancer circulating tumor cell xenotransplantation model. Analysis of AKT isoform‐specific knockdowns in CTC‐MCC‐41 reveals differentially regulated proteins and phospho‐proteins by liquid chromatography coupled mass spectrometry. Circulating tumor cells
Daniel J. Smit, Thais Pereira‐Veiga, Helena Brauer, Michael Horn, Paula Nissen, Thomas Mair, Bente Siebels, Hannah Voß, Ruimeng Zhuang, Marie‐Therese Haider, Desiree Loreth, Margarita Iskhakova, Bele Lindemann, Julian Kött, Laure Cayrefourcq, Jasmin Wellbrock, Hartmut Schlüter, Klaus Pantel, Catherine Alix‐Panabières, Manfred Jücker   +19 more
wiley   +1 more source

Stem-like and highly invasive prostate cancer cells expressing CD44v8-10 marker originate from CD44-negative cells [PDF]

, 2018
In human prostate cancer (PCa), the neuroendocrine cells, expressing the prostate cancer stem cell (CSC) marker CD44, may be resistant to androgen ablation and promote tumor recurrence.
Campese, Af, Canipari, R, D'Amore, A, De Cesaris, P, Di Stefano, C, Filippini, A, Fiori, Me, Fontanella, Ra, Grazioli, P, Padula, F, Pesce, M, Regno, M, Riccioli, A., Starace, D, Stoppacciaro, A, Ziparo, E   +15 more
core   +2 more sources

Inhibitor of DNA binding‐1 is a key regulator of cancer cell vasculogenic mimicry

Molecular Oncology, EarlyView.
Elevated expression of transcriptional regulator inhibitor of DNA binding 1 (ID1) promoted cancer cell‐mediated vasculogenic mimicry (VM) through regulation of pro‐angiogenic and pro‐cancerous genes (e.g. VE‐cadherin (CDH5), TIE2, MMP9, DKK1). Higher ID1 expression also increased metastases to the lung and the liver.
Emma J. Thompson, Emma L. Dorward, Kristyn Jurrius, Nathalie Nataren, Markus Tondl, Kay K. Myo Min, Michaelia P. Cockshell, Anahita Fouladzadeh, John Toubia, Mark DeNichilo, Delphine Merino, Claudine S. Bonder   +11 more
wiley   +1 more source

Basosquamous Carcinoma Arising from the Vulva: A Case Report

Case Reports in Oncology
Introduction: Basosquamous carcinoma (BSC) of the vulva is an uncommon tumor that primarily consists of basal cell carcinoma with squamous differentiation.
Fatma Saadallah, Ayoub Ghazouani, Ines Zemni, Haykel Turki, Houyem Mansouri, Ghada Sahraoui, Tarek Ben Dhiab   +6 more
doaj   +1 more source

Resistance to anti-PD-1-based immunotherapy in basal cell carcinoma: a case report and review of the literature

Journal for ImmunoTherapy of Cancer, 2018
Background Immunotherapy with immune checkpoint inhibitors has radically changed the management of a broad spectrum of tumors. In contrast, only very limited information is available about the efficacy of these therapies in non-melanoma skin cancers ...
Francesco Sabbatino, Antonio Marra, Luigi Liguori, Giosuè Scognamiglio, Celeste Fusciello, Gerardo Botti, Soldano Ferrone, Stefano Pepe   +7 more
doaj   +1 more source

Vismodegib: the first drug approved for advanced and metastatic basal cell carcinoma.

Journal of Postgraduate Medicine, 2013
Treatment of basal cell carcinoma (BCC) usually involves surgical interventions and laser ablation, but in locally advanced BCC, which arise either from earlier untreated lesions or from recurrence of aggressive BCC, surgery and radiotherapy are not ...
A. Dubey, S. Dubey, S. Handu, M. Qazi
semanticscholar   +1 more source

MET and NF2 alterations confer primary and early resistance to first‐line alectinib treatment in ALK‐positive non‐small‐cell lung cancer

Molecular Oncology, EarlyView.
Alectinib resistance in ALK+ NSCLC depends on treatment sequence and EML4‐ALK variants. Variant 1 exhibited off‐target resistance after first‐line treatment, while variant 3 and later lines favored on‐target mutations. Early resistance involved off‐target alterations, like MET and NF2, while on‐target mutations emerged with prolonged therapy.
Jie Hu, Ning Ding, Xiaobo Xu, Yedan Chen, Yong Zhang, Jingwen Liu, Jiebai Zhou, Hairong Bao, Donghui Zhang, Yijun Song, Yang Shao, Yuanlin Song   +11 more
wiley   +1 more source

Clinical utility of ingenol mebutate in the management of actinic keratosis. Perspectives from clinical practice [PDF]

, 2018
Actinic keratoses (AKs) are epidermal cutaneous neoplasia observed predominantly in middle-aged and older subjects with mainly photo type I and photo type II on sun-exposed surfaces as a result of DNA damage.
Bernardini, Nicoletta, Potenza, Concetta, Proietti, Ilaria, Skroza, Nevena   +3 more
core   +1 more source

Investigational agents in metastatic basal cell carcinoma: focus on vismodegib

Journal of Experimental Pharmacology, 2012
Nicolas Batty,1 Ellen Kossoff,2 Grace K Dy11Department of Medicine, Roswell Park Cancer Center, Buffalo, NY, USA; 2Department of Pharmacy, Roswell Park Cancer Center, Buffalo, NY, USAAbstract: Vismodegib (GDC-0449, 2-chloro-N-(4-chloro-3-(pyridin-2-yl ...
Batty N, Kossoff E, Dy GK
doaj